1 års afkast (CAGR)
-83.94%
Ascelia Pharma AB (publ) Exchange (ST, SEK)
ACE.ST
0.62
-0.02 (-2.83%)
HealthcareBiotechnology
Loading...
3 års afkast (CAGR)
-38.78%
5 års afkast (CAGR)
-50.30%
10 års afkast (CAGR)
-
Computer Modeling Group 2027 Q1 - Vender turnarounds sjældent?
Læs mereMarkedsværdi
82.66M
Pris/omsætning
-
Ent værdi
55.01M
Pris/bog
0.92
Udbytte afkast
0.00%
Vekst år
-
Udbyttevækst
-
FCF-udbetaling
0.00%
Efterfølgende P/E
-
PEG
-
Fremtidig P/E
14.30
EPS-vekst
-23.70%
Oplysninger om aktier
Hvad er en børs? Drift, aktører, eksempler
Læs mereAktiediagram
Loading...
Aktiekurs-data
| Åbning | 0.64 |
| Daglig høj | 0.65 |
| Daglig lav | 0.61 |
| Daglig volumen | 310K |
| Højeste gennem alle tider | 43.65 |
| 1 års analytiker estimat | 2.39 |
| Beta | 0.85 |
| EPS (TTM) | -0.46 |
| Udbytte pr. aktie | 0.00 |
| Ex-div dato | - |
| Næste dato for resultatpræsentation | - |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| ACE.ST | S&P500 | |
| Nuværende prisfald fra top notering | -98.58% | -2.19% |
| Højeste prisfald | -98.91% | -56.47% |
| Højeste efterår dato | 14 Jul 2026 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -64.10% | -10.69% |
| Gennemsnitlig tid til nyt højdepunkt | 99 days | 12 days |
| Maks. tid til nyt højdepunkt | 1445 days | 1805 days |
Nyheder
MALMÖ, SE / ACCESS Newswire / September 10, 2026 / (STO:ACE) completed the previously scheduled Type A meeting with the U. Food and Drug Administration (FDA) on September 9, 2026, regarding the Comple...
10. september 2026
Despite a surprise complete response letter, Ascelia Pharma remains confident in Orviglans' approval path, with a pivotal FDA Type A meeting set for September 9th and partnership interest intact.
20. august 2026
MALMÖ, SE / ACCESS Newswire / August 17, 2026 / Ascelia Pharma AB (publ) (STO:ACE), a biotech company focused on improving the lives of people living with rare cancer conditions, today announced that ...
17. august 2026
MALMÖ, SE / ACCESS Newswire / July 15, 2026 / Ascelia Pharma (STO:ACE), a biotech company focused on improving the lives of people with rare cancer conditions, today announces that CFO Anton Hansson w...
15. juli 2026
MALMÖ, SE / ACCESS Newswire / July 12, 2026 / Ascelia Pharma (STO:ACE) - Ascelia Pharma AB (publ) (STO:ACE), a biopharmaceutical company focused on improving the lives of people living with rare cance...
12. juli 2026
MALMÖ, SE / ACCESS Newswire / June 30, 2026 / Ascelia Pharma AB (publ) (STO:ACE), a biotech company focused on improving the life of people living with rare cancer conditions, today announced the fili...
30. juni 2026
Ascelia Pharma AB (FRA:7ZA) advances towards FDA approval for Orbiglanz while navigating financial hurdles and strategic partnerships.
12. maj 2026
MALMÖ, SE / ACCESS Newswire / April 30, 2026 / Ascelia Pharma (STO:ACE): During April, the registered number of shares and votes in Ascelia Pharma AB ("Ascelia Pharma") has increased due to the direct...
30. april 2026
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. MALMÖ, SE / ACCESS Newswire / April 9,...
9. april 2026
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. MALMÖ, SE / ACCESS Newswire / March 30...
30. marts 2026